tiprankstipranks
Trending News
More News >

scPharmaceuticals reports Q1 EPS (37c), consensus (28c)

Reports Q1 revenue $11.75M, consensus $11.63M. “The FUROSCIX indication expansion into chronic kidney disease represents encouraging progress towards accomplishing scPharmaceuticals (SCPH)’ long-term growth initiatives for the product’s lifecycle. Our sales force is in the field calling on nephrologists and we are pleased with the receptivity towards FUROSCIX from these physicians,” stated John Tucker, President and Chief Executive Officer of scPharmaceuticals. “Similar to other pharmaceutical commercial organizations, scPharmaceuticals faced seasonal headwinds in the first quarter. Starting in March and in the first half of Q2, we have seen an increase in the number of Medicare-covered patients who have reached their annual out-of-pocket maximum or have signed up for Part D smoothing. Historically, the reduction in cost burden to patients has been associated with a meaningful rise in FUROSCIX filled prescription volumes. As a result, in Q2, we have seen a corresponding acceleration in our fill rate, prescriptions written and in units shipped to patients. We view this trend as a favorable tailwind that we expect will support FUROSCIX growth through Q2 and for the balance of 2025.”

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue